Artelon® Product Line Under New Ownership, Relocates Operations from Sweden to U.S. (press release)
International Life Sciences, LLC (dba, Artelon®) acquired the assets of Artimplant® AB in January 2014 and has relocated operations from Sweden to the United States. This international relocation allows Artelon® to more closely engage its largest customer base and provide additional opportunities for product development that were not previously available.
Adam Barese now serves as the Chief Executive Officer of the Organization. After garnering almost two decades of medical industry experience with Wyeth Pharmaceuticals, in sales, marketing, and sales management, and as a orthopedic/biologic sales director with Genzyme in the Biosurgical division, Barese most recently built a multistate medical distributorship which included the Artelon® products as part of his portfolio.
Jim Tyson now serves as the US VP of sales and marketing. Mr. Tyson is a 25-year veteran of the orthopedic medical device industry, successful stents at Howmedica as a reconstructive and trauma sales representative and then as a regional and national sales manager at SBI, Nutek Orthopedic, and Artimplant®.
Artelon continues to work with many of the worldwide distributors that previously sold the Artelon® Tissue Reinforcement products, and is rapidly expanding the number of U.S. and international distributorships to provide more substantial and highly qualified market coverage.
The company will be showcasing its products at multiple upcoming events, including the American College of Foot and Ankle Surgeons (ACFAS) this week in Orlando, FL.
Artelon markets and sells the Artelon® Tissue Reinforcement products worldwide and will be establishing manufacturing operations in the United States.
Artelon® is a unique, degradable biomaterial that serves as a scaffold for tissue ingrowth and provides temporary support for healing tissue. Artelon® was developed specifically for medical applications and has clinical documentation with long follow-up periods. Thousands of patients worldwide have been successfully treated with Artelon® implants.
The key features of Artelon® are:
- Serves as a temporary scaffold for the body’s own cells while it degrades and integrates with the body over a six year period
- Stabilizes and shares load during the healing period providing long term support for healing tissue
- Excellent biocompatibility to human tissue
- Synthetic material eliminates the risk of disease transmission or collagen reactions
Artelon® Tissue Reinforcement is intended for use in general surgical procedures for reinforcement of soft tissue. It is also intended for reinforcement of soft tissues that are repaired by sutures or suture anchors, during tendon and ligament repair surgery.
Contact:
Artelon
Adam Barese
Chief Executive Officer
(01) 615-783-1712
Email
www.Artelon.com
Read more news from Artelon.